TheMarker: a Comprehensive Database of Therapeutic Biomarkers

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2023 Oct 18

PMID 37850638

Authors

Yintao Zhang

Ying Zhou

Yuan Zhou

Xinyuan Yu

Xinyi Shen

Yanfeng Hong

Yuxin Zhang

Shanshan Wang

Minjie Mou

Jinsong Zhang

Lin Tao

Jianqing Gao

Yunqing Qiu

YuZong Chen

Feng Zhu

Affiliations

Soon will be listed here.

Abstract

Distinct from the traditional diagnostic/prognostic biomarker (adopted as the indicator of disease state/process), the therapeutic biomarker (ThMAR) has emerged to be very crucial in the clinical development and clinical practice of all therapies. There are five types of ThMAR that have been found to play indispensable roles in various stages of drug discovery, such as: Pharmacodynamic Biomarker essential for guaranteeing the pharmacological effects of a therapy, Safety Biomarker critical for assessing the extent or likelihood of therapy-induced toxicity, Monitoring Biomarker indispensable for guiding clinical management by serially measuring patients' status, Predictive Biomarker crucial for maximizing the clinical outcome of a therapy for specific individuals, and Surrogate Endpoint fundamental for accelerating the approval of a therapy. However, these data of ThMARs has not been comprehensively described by any of the existing databases. Herein, a database, named 'TheMarker', was therefore constructed to (a) systematically offer all five types of ThMAR used at different stages of drug development, (b) comprehensively describe ThMAR information for the largest number of drugs among available databases, (c) extensively cover the widest disease classes by not just focusing on anticancer therapies. These data in TheMarker are expected to have great implication and significant impact on drug discovery and clinical practice, and it is freely accessible without any login requirement at: https://idrblab.org/themarker.

Citing Articles

Lung Cancer Biomarker Database (LCBD): a comprehensive and curated repository of lung cancer biomarkers.

Li Y, Tong Z, Yang Y, Wang Y, Wen L, Li Y BMC Cancer. 2025; 25(1):478.

PMID: 40089661 DOI: 10.1186/s12885-025-13883-w.

Metabolomics-driven approaches for identifying therapeutic targets in drug discovery.

Pan S, Yin L, Liu J, Tong J, Wang Z, Zhao J MedComm (2020). 2024; 5(11):e792.

PMID: 39534557 PMC: 11555024. DOI: 10.1002/mco2.792.

NEK2 is a potential pan-cancer biomarker and immunotherapy target.

Zhang L, Li Y, Deng J, Liao W, Liu T, Shen F Discov Oncol. 2024; 15(1):626.

PMID: 39505744 PMC: 11541068. DOI: 10.1007/s12672-024-01519-7.

GTSE1-driven ZEB1 stabilization promotes pulmonary fibrosis through the epithelial-to-mesenchymal transition.

Jin H, Park S, Lee J, Park H, Jeong M, Lee H Mol Ther. 2024; 32(11):4138-4157.

PMID: 39342428 PMC: 11573610. DOI: 10.1016/j.ymthe.2024.09.029.

DrugRepoBank: a comprehensive database and discovery platform for accelerating drug repositioning.

Huang Y, Dong D, Zhang W, Wang R, Lin Y, Zuo H Database (Oxford). 2024; 2024.

PMID: 38994794 PMC: 11240114. DOI: 10.1093/database/baae051.

References

Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z . DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2022; 51(D1):D1263-D1275. PMC: 9825618. DOI: 10.1093/nar/gkac812. View

Argollo M, Kotze P, Kakkadasam P, DHaens G . Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. Nat Rev Gastroenterol Hepatol. 2020; 17(11):702-710. DOI: 10.1038/s41575-020-0352-2. View

Xue W, Fu T, Deng S, Yang F, Yang J, Zhu F . Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram. ACS Chem Neurosci. 2022; 13(3):340-351. DOI: 10.1021/acschemneuro.1c00694. View

Barrett T, Wilhite S, Ledoux P, Evangelista C, Kim I, Tomashevsky M . NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41(Database issue):D991-5. PMC: 3531084. DOI: 10.1093/nar/gks1193. View

Xia W, Zheng L, Fang J, Li F, Zhou Y, Zeng Z . PFmulDL: a novel strategy enabling multi-class and multi-label protein function annotation by integrating diverse deep learning methods. Comput Biol Med. 2022; 145:105465. DOI: 10.1016/j.compbiomed.2022.105465. View

Yang Q, Li B, Tang J, Cui X, Wang Y, Li X . Consistent gene signature of schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data. Brief Bioinform. 2019; 21(3):1058-1068. DOI: 10.1093/bib/bbz049. View

Aulin L, de Lange D, Saleh M, van der Graaf P, Voller S, van Hasselt J . Biomarker-Guided Individualization of Antibiotic Therapy. Clin Pharmacol Ther. 2021; 110(2):346-360. PMC: 8359228. DOI: 10.1002/cpt.2194. View

Hostallero D, Wei L, Wang L, Cairns J, Emad A . Preclinical-to-clinical Anti-cancer Drug Response Prediction and Biomarker Identification Using TINDL. Genomics Proteomics Bioinformatics. 2023; 21(3):535-550. PMC: 10787192. DOI: 10.1016/j.gpb.2023.01.006. View

Yin J, Li F, Zhou Y, Mou M, Lu Y, Chen K . INTEDE: interactome of drug-metabolizing enzymes. Nucleic Acids Res. 2020; 49(D1):D1233-D1243. PMC: 7779056. DOI: 10.1093/nar/gkaa755. View

10.

Yurchenko A, Pop O, Ighilahriz M, Padioleau I, Rajabi F, Sharpe H . Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma. Clin Cancer Res. 2022; 28(7):1422-1432. PMC: 9365352. DOI: 10.1158/1078-0432.CCR-21-3764. View

11.

He H, Shi M, Lin Y, Zhan C, Wu R, Bi C . HFBD: a biomarker knowledge database for heart failure heterogeneity and personalized applications. Bioinformatics. 2021; 37(23):4534-4539. DOI: 10.1093/bioinformatics/btab470. View

12.

Ai H, Chen W, Zhang L, Huang L, Yin Z, Hu H . Predicting Drug-Induced Liver Injury Using Ensemble Learning Methods and Molecular Fingerprints. Toxicol Sci. 2018; 165(1):100-107. DOI: 10.1093/toxsci/kfy121. View

13.

Brown M, Li Z, Le Cao K . Biomarker development for axial spondyloarthritis. Nat Rev Rheumatol. 2020; 16(8):448-463. DOI: 10.1038/s41584-020-0450-0. View

14.

Heerspink H, Greene T, Tighiouart H, Gansevoort R, Coresh J, Simon A . Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019; 7(2):128-139. DOI: 10.1016/S2213-8587(18)30314-0. View

15.

Riviere-Cazaux C, Lacey J, Carlstrom L, Laxen W, Munoz-Casabella A, Hoplin M . Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas. Neurooncol Adv. 2023; 5(1):vdad061. PMC: 10259246. DOI: 10.1093/noajnl/vdad061. View

16.

Wallington-Beddoe C, Mynott R . Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol. 2021; 14(1):151. PMC: 8461914. DOI: 10.1186/s13045-021-01162-7. View

17.

Lipska K, Krumholz H . Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?. JAMA. 2017; 317(10):1017-1018. PMC: 5350060. DOI: 10.1001/jama.2017.0029. View

18.

Zhang J, Yan S, Li R, Wang G, Kang S, Wang Y . CRMarker: A manually curated comprehensive resource of cancer RNA markers. Int J Biol Macromol. 2021; 174:263-269. DOI: 10.1016/j.ijbiomac.2021.01.186. View

19.

Stefaniak J, Huber K . Importance of Quantifying Drug-Target Engagement in Cells. ACS Med Chem Lett. 2020; 11(4):403-406. PMC: 7153009. DOI: 10.1021/acsmedchemlett.9b00570. View

20.

Wang X, Li F, Qiu W, Xu B, Li Y, Lian X . SYNBIP: synthetic binding proteins for research, diagnosis and therapy. Nucleic Acids Res. 2021; 50(D1):D560-D570. PMC: 8728148. DOI: 10.1093/nar/gkab926. View